James Mohler, MD

James Mohler, MD, associate director for translational research and a professor of oncology at Roswell Park Comprehensive Cancer Center, discusses the rationale for the latest updates to the National Comprehensive Cancer Network (NCCN) guidelines for genetic testing in prostate cancer.

Mohler says the most important update has been making clear what a family history should consist of when addressing a man with prostate cancer. Too often, the family history is recorded as positive or negative, sometimes including what relative had prostate cancer, but the family history does not capture the age of diagnosis, treatment received, and whether or not the disease led to either metastatic disease or death in that relative.

The updates to the NCCN guidelines prescribed what family history should be collected, as well as other things that should be captured, such as hereditary syndromes. Most importantly, the updates also noted the importance of identifying where a family member with prostate cancer is in the family tree. By doing a better job at capturing family history, this information can be utilized more in clinical practice, says Mohler.

Videos

James Mohler, MD, discusses the rationale for the latest updates to the National Comprehensive Cancer Network guidelines for genetic testing in prostate cancer.

Updates in NCCN Guidelines for Molecular Testing in Prostate Cancer

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses sequencing agents in prostate cancer.

The FDA has approved 5 agents in the last 5 years, each of which extend survival by 2-5 months in patients with prostate cancer

There remains a need to determine the appropriate sequencing of these agents

Research is being conducted to develop a biomarker of response to hormonal therapy

Research is being conducted in mouse models to reach an answer quickly, rather than wait for a clinical trial

Sequencing New Agents in Prostate Cancer

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses how his laboratory is working to improve the efficacy of abiraterone for the treatment of prostate cancer.

A better understanding of the last 2 steps of the backdoor pathway could lead to improved treatment as androgen synthesis inhibitors (abiraterone, TAK-700, and TOK-001) all work upstream, far from DHT

Researchers are testing whether an attack next to the preferred androgen DHT will improve response to FDA-approved agents

Androgen deprivation therapy may be more effective if DHT levels in the tissue are reduced to 0

James Mohler, MD | Authors

Articles

Updates in NCCN Guidelines for Molecular Testing in Prostate Cancer

Sequencing New Agents in Prostate Cancer

Improving the Efficacy of Abiraterone